- Home
- AMGN vs C Comparison
AMGN vs C Comparison
Compare AMGN & C Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- C
- Stock Information
- Founded
- AMGN 1980
- C 1812
- Country
- AMGN United States
- C United States
- Employees
- AMGN N/A
- C N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- C Major Banks
- Sector
- AMGN Health Care
- C Finance
- Exchange
- AMGN Nasdaq
- C Nasdaq
- Market Cap
- AMGN 150.8B
- C 176.2B
- IPO Year
- AMGN N/A
- C N/A
- Fundamental
- Price
- AMGN $295.53
- C $101.53
- Analyst Decision
- AMGN Hold
- C Buy
- Analyst Count
- AMGN 15
- C 15
- Target Price
- AMGN $313.57
- C $104.63
- AVG Volume (30 Days)
- AMGN 2.0M
- C 13.3M
- Earning Date
- AMGN 11-04-2025
- C 10-14-2025
- Dividend Yield
- AMGN 3.21%
- C 2.36%
- EPS Growth
- AMGN 110.88
- C 103.92
- EPS
- AMGN 12.23
- C 7.10
- Revenue
- AMGN $34,917,000,000.00
- C $75,384,000,000.00
- Revenue This Year
- AMGN $8.90
- C $23.37
- Revenue Next Year
- AMGN $1.79
- C $3.12
- P/E Ratio
- AMGN $24.23
- C $14.30
- Revenue Growth
- AMGN 12.88
- C 9.16
- 52 Week Low
- AMGN $253.30
- C $55.51
- 52 Week High
- AMGN $335.88
- C $105.59
- Technical
- Relative Strength Index (RSI)
- AMGN 54.03
- C 57.65
- Support Level
- AMGN $288.26
- C $98.31
- Resistance Level
- AMGN $294.81
- C $101.94
- Average True Range (ATR)
- AMGN 6.05
- C 2.59
- MACD
- AMGN -0.40
- C 0.35
- Stochastic Oscillator
- AMGN 46.63
- C 91.29
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About C Citigroup Inc.
Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.